Attovia Therapeutics, Inc. (ATTO) has 7 open-market insider trades by 5 insiders since 2026. Over the last six months insiders net bought $42.2M. The most active filer is Goldman SACHS GROUP Inc..
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Goldman SACHS GROUP Inc. | — | — | 2 | $14.8M | 2026-08-06 |
| Colin Walsh | Dir | — | 2 | $14.8M | 2026-08-06 |
| Frazier Life Sciences XI, L.P. | 10% Owner | — | 1 | $10.0M | 2026-08-06 |
| venBio Global Strategic Fund IV, L.P. | 10% Owner | — | 1 | $6.5M | 2026-08-06 |
| Sanofi | 10% Owner | — | 1 | $5.1M | 2026-08-06 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Sanofi | 10% Owner | Buy | $5.1M | 2026-08-06 |
| venBio Global Strategic Fund IV, L.P. | 10% Owner | Buy | $6.5M | 2026-08-06 |
| Frazier Life Sciences XI, L.P. | 10% Owner | Buy | $10.0M | 2026-08-06 |
| Goldman SACHS GROUP Inc. | — | Buy | $10.3M | 2026-08-05 |
| Colin Walsh | Director | Buy | $2.2M | 2026-08-05 |
| Colin Walsh | Director | Sell | $2.2M |
Companies that share insiders with ATTO, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2026-08-05 |